Cover Image
Market Research Report

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Published by GlobalData Product code 232348
Published Content info 42 Pages
Immediate Delivery Available
Price
Back to Top
Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020
Published: January 31, 2012 Content info: 42 Pages
Description

Summary

GlobalData's pharmaceuticals report, "Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Insulin Degludec sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Insulin Degludec
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Insulin Degludec including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Insulin Degludec in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1 Diabetes
  • 2.2. Epidemiology
    • 2.2.1. Prevalence
    • 2.2.2. Mortality
  • 2.3. Etiology and Risk Factors
    • 2.3.1. Obesity
    • 2.3.2. Sedentary Lifestyle
    • 2.3.3. Family History and Genetics
    • 2.3.4. Ethnicity
    • 2.3.5. Old Age
  • 2.4. Economic Impact of Diabetes
  • 2.5. GlobalData Report Guidance

3. Type 2 Diabetes: Market Characterization

  • 3.1. Type 2 Diabetes Market
  • 3.2. Type 2 Diabetes Market Forecasts and CAGR
  • 3.3. Type 2 Diabetes Market: Drivers and Restraints
    • 3.3.1. Drivers
    • 3.3.2. Restraints

4. Classification of Diabetes

  • 4.1. Types of Diabetes
    • 4.1.1. Type1 Diabetes
    • 4.1.2. Type 2 Diabetes
    • 4.1.3. Gestational Diabetes
  • 4.2 Diabetes Complications
    • 4.2.1. Cardiovascular Disease
    • 4.2.2. Nephropathy
    • 4.2.3. Neuropathy
    • 4.2.4. Amputation
    • 4.2.5. Retinopathy

5. Evolution of Anti-Diabetic Treatments

6. Medications

  • 6.1. Insulin
  • 6.2. Oral Medications
    • 6.2.1. Sulfonylureas (SUR)
    • 6.2.2. Biguanides (BGDs)
    • 6.2.3. Alpha-Glucosidase Inhibitors (AGI)
    • 6.2.4. Meglitinides
    • 6.2.5. Thiazolidinediones (TZDs)
    • 6.2.6. Dipeptidyl Peptidase IV (DPP-4) Inhibitors
    • 6.2.7. Oral Combination Therapy
  • 6.3. Other Injectionable Medications
    • 6.3.1. Pramlintide
    • 6.3.2. Exenatide
  • 6.4. Market Share as per Classes in Type 2 Diabetes

7. Insulin Degludec

  • 7.1. Introduction
  • 7.2. Mechanism of Action
  • 7.3. Clinical Studies
  • 7.4. Factors Affecting Sales of Insulin Degludec
    • 7.4.1. Novel Ultra Long-Acting Insulin
    • 7.4.2. Growing Insulin Market
    • 7.4.3. Higher Dosing Convenience
    • 7.4.4. Reduced Incidence of Hypoglycemia
  • 7.5. Drug Evaluation
    • 7.5.1. Drug Risk Benefit Score
    • 7.5.2. Intensity of Competition
  • 7.6. Sales Forecasts
    • 7.6.1. Target Patient Pool
    • 7.6.2. Dosing
    • 7.6.3. Annual Cost of Therapy
    • 7.6.4. Market Penetration
    • 7.6.5. Sales Projections of Insulin Degludec

8 Diabetes Market: Appendix

  • 8.1. Market Definitions
  • 8.2. List of Abberiviations
  • 8.3. Research Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Forecasting
    • 8.3.4. Number of patients approved to take the drug
    • 8.3.5. Net Penetration of Drug
    • 8.3.6. Net Annual Dosing
    • 8.3.7. Annual Cost of Therapy
  • 8.4. Drug Sales Estimates Model
  • 8.5. Contact Us
  • 8.6. Disclaimer
  • 8.7. Sources

List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($m), 2010
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
  • Table 8: Diabetes Drugs Evolution
  • Table 9: Drug Risk Benefit Score of Insulin Degludec
  • Table 10: Types of Insulin
  • Table 11: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020
  • Table 12: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020
  • Table 13: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020
  • Table 14: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020
  • Table 15: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020
  • Table 16: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020
  • Table 17: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020
  • Table 18: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020

List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030
  • Figure 3: Diabetes, World, Mortality, 2010
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020
  • Figure 6: Mechanism of Action of Sulfonylureas
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
  • Figure 9: Mechanism of Action of Thiazolidinediones
  • Figure 10: Mechanism of Action of DPP IV Inhibitors
  • Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010
  • Figure 12: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020
  • Figure 13: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020
  • Figure 14: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020
  • Figure 15: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020
  • Figure 16: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020
  • Figure 17: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020
  • Figure 18: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020
  • Figure 19: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020
  • Figure 20: Insulin Degludec, Type 2 Diabetes, Sales Distribution by Country (%), 2020
  • Figure 21: Patients Approved for the Drug
Back to Top